A recent study using a set of eight genes, including MIEN1, revealed a moderate response to adjuvant Trastuzumab therapy even in HER2 negative breast cancer, confirming the importance of this gene in responses to neo-adjuvant therapies [32]. This evidence concerns the gene ERBB2 and breast cancer.